[go: up one dir, main page]

MX2009001778A - Peptidos pcpa inmunogenicos y usos de los mismos. - Google Patents

Peptidos pcpa inmunogenicos y usos de los mismos.

Info

Publication number
MX2009001778A
MX2009001778A MX2009001778A MX2009001778A MX2009001778A MX 2009001778 A MX2009001778 A MX 2009001778A MX 2009001778 A MX2009001778 A MX 2009001778A MX 2009001778 A MX2009001778 A MX 2009001778A MX 2009001778 A MX2009001778 A MX 2009001778A
Authority
MX
Mexico
Prior art keywords
polypeptides
methods
immunogenic
compositions
immunogenic pcpa
Prior art date
Application number
MX2009001778A
Other languages
English (en)
Inventor
David E Briles
Susan K Hollingshead
Jeremy Yethon
Joe Wang
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of MX2009001778A publication Critical patent/MX2009001778A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

En la presente se proporcionan composiciones y métodos para inducir una respuesta inmunitaria con Streptococcus pneumoniae. De manera más particular, las composiciones y métodos se relacionan con polipéptidos inmunogénicos que incluyen fragmentos de PcpA y variantes de los mismos y ácidos nucleicos, vectores y células transfectadas que codifican o expresan los polipéptidos. También se describen métodos de elaboración y uso de los polipéptidos inmunogénicos.
MX2009001778A 2006-08-17 2007-08-17 Peptidos pcpa inmunogenicos y usos de los mismos. MX2009001778A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82271506P 2006-08-17 2006-08-17
US82734806P 2006-09-28 2006-09-28
US91717807P 2007-05-10 2007-05-10
PCT/US2007/076180 WO2008022302A2 (en) 2006-08-17 2007-08-17 Immunogenic pcpa polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2009001778A true MX2009001778A (es) 2009-05-22

Family

ID=38942273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001778A MX2009001778A (es) 2006-08-17 2007-08-17 Peptidos pcpa inmunogenicos y usos de los mismos.

Country Status (11)

Country Link
US (2) US20110002962A1 (es)
EP (2) EP2059807B1 (es)
JP (3) JP5081243B2 (es)
KR (1) KR101523108B1 (es)
CN (2) CN107056902A (es)
AU (1) AU2007285775B2 (es)
BR (1) BRPI0715975A2 (es)
CA (2) CA2660743C (es)
IL (1) IL197094A (es)
MX (1) MX2009001778A (es)
WO (3) WO2008022298A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
MX2009001778A (es) * 2006-08-17 2009-05-22 Uab Research Foundation Peptidos pcpa inmunogenicos y usos de los mismos.
WO2008124920A1 (en) * 2007-04-12 2008-10-23 The Governors Of The University Of Alberta Urine based detection of a disease state caused by a pneumococcal infection
JP5697991B2 (ja) * 2008-02-01 2015-04-08 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 診断的アッセイ
MX2010011412A (es) * 2008-04-16 2010-11-12 Glaxosmithkline Biolog Sa Vacuna.
US20110171224A1 (en) * 2008-05-22 2011-07-14 Orihuela Carlos J PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
MX2011006922A (es) * 2008-12-24 2012-06-12 Netherlands Vaccine Inst Polipeptidos de neumolisina (ply) modificada a partir de streptococcus pneumonia.
JP5204036B2 (ja) * 2009-05-28 2013-06-05 旭化成株式会社 肺炎球菌の検出方法
KR20120107121A (ko) * 2009-12-22 2012-09-28 사노피 파스퇴르 리미티드 면역원성 조성물
CN102939105B (zh) 2009-12-22 2016-11-16 赛诺菲巴斯德有限公司 免疫原性组合物和相关的方法
US20110262989A1 (en) * 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
AU2011336366B2 (en) * 2010-12-03 2016-05-12 Sanofi Pasteur Limited Composition for immunization against Streptococcus pneumoniae
US8603769B2 (en) * 2011-10-07 2013-12-10 Becton, Dickinson And Company Method for direct and rapid identification of microorganisms and antimicrobial susceptibility testing from positive blood cultures
CA2865582C (en) 2012-02-29 2021-03-16 Becton, Dickinson And Company Formulations and process for isolating viable microorganism from positive blood cultures
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN104306965B (zh) * 2014-10-31 2017-05-10 康希诺生物股份公司 预防肺炎链球菌感染性疾病的免疫原性组合物及制备方法
CN108601754A (zh) * 2015-12-01 2018-09-28 宝洁公司 抑制肉毒碱向三甲胺（tma）转化的方法
JP6770805B2 (ja) * 2016-01-28 2020-10-21 旭化成株式会社 検体中の特定の細菌を検出する方法
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN106636149B (zh) * 2017-01-03 2019-10-25 内蒙古农业大学 斯氏副柔线虫丝氨酸/苏氨酸蛋白激酶Pj_STPK基因克隆、原核表达方法及应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110387427A (zh) * 2018-04-16 2019-10-29 马东礼 用于检测肺炎链球菌的引物组及试剂盒

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US6027734A (en) 1991-02-15 2000-02-22 Uab Research Foundation Mucosal administration of pneumococcal antigens
US6592876B1 (en) * 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5792457A (en) * 1991-05-03 1998-08-11 The Rockefeller University Antibody recognizing endothelial cell ligand for leukocyte CR3
US5854416A (en) * 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US6312944B1 (en) * 1991-11-14 2001-11-06 The United States Of America As Represented By The Department Of Health And Human Services Pneumococcal fimbrial protein A
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US6420135B1 (en) * 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
IS4518A (is) 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
EP2053126A1 (en) 1998-07-27 2009-04-29 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
CA2379327A1 (en) * 1999-06-10 2000-12-21 Uab Research Foundation Pneumococcal surface protein combination vaccine
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP2258842A1 (en) 2001-04-16 2010-12-08 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
AU2003226131A1 (en) 2002-03-28 2003-10-13 Bristol-Myers Squibb Company Novel human cell surface protein with immunoglobulin folds, bgs-19
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
EP1615950A2 (en) * 2003-04-15 2006-01-18 Intercell AG S. pneumoniae antigens
EP1694359A2 (en) * 2003-11-10 2006-08-30 UAB Research Foundation Compositions for reducing bacterial carriage and cns invasion and methods of using same
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
EP3020411A1 (en) * 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
MX2009001778A (es) * 2006-08-17 2009-05-22 Uab Research Foundation Peptidos pcpa inmunogenicos y usos de los mismos.
JP5697991B2 (ja) * 2008-02-01 2015-04-08 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 診断的アッセイ
GB201104897D0 (en) * 2011-03-23 2011-05-04 Immunobiology Ltd Method for the production of protein complexes and vaccine compositions comprising the same

Also Published As

Publication number Publication date
WO2008022299A1 (en) 2008-02-21
CA2660743A1 (en) 2008-02-21
EP2059807A4 (en) 2010-01-27
CN101573374A (zh) 2009-11-04
AU2007285775A1 (en) 2008-02-21
JP2013155205A (ja) 2013-08-15
JP5081243B2 (ja) 2012-11-28
IL197094A (en) 2014-12-31
CA2660743C (en) 2015-11-24
JP5932711B2 (ja) 2016-06-08
WO2008022298A3 (en) 2008-04-03
WO2008022302A3 (en) 2008-04-03
WO2008022298A2 (en) 2008-02-21
CA2661210A1 (en) 2008-02-21
EP2059807A1 (en) 2009-05-20
WO2008022302A2 (en) 2008-02-21
US20110002962A1 (en) 2011-01-06
BRPI0715975A2 (pt) 2014-03-18
US20100227341A1 (en) 2010-09-09
KR20090071551A (ko) 2009-07-01
CN107056902A (zh) 2017-08-18
JP2010501012A (ja) 2010-01-14
US8252546B2 (en) 2012-08-28
EP2081953A2 (en) 2009-07-29
JP2010501078A (ja) 2010-01-14
KR101523108B1 (ko) 2015-05-26
EP2059807B1 (en) 2013-02-20
AU2007285775B2 (en) 2011-03-03
IL197094A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
MX2009001778A (es) Peptidos pcpa inmunogenicos y usos de los mismos.
IL250946B (en) Nanobodies against tumor necrosis factor-alpha (tnf-alpha)
WO2005121331A3 (en) Truncated galnact2 polypeptides and nucleic acids
WO2015048333A3 (en) Nutritive polypeptides and formulations thereof, and methods of production and use thereof
MX2014001383A (es) Colageno 7 y metodos relacionados.
EP4050027A3 (en) Cx3cr1-binding polypeptides
BR112018012694A2 (pt) composição de célula dendrítica, vacina de célula dendrítica, composição e kit
HK1199711A1 (en) Bioconjugate vaccines made in prokaryotic cells
WO2010065876A3 (en) Methods and compositions related to th-1 dendritic cells
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
WO2011067758A3 (en) Immunogenic fragments and multimers from streptococcus pneumoniae proteins
WO2007044083A3 (en) Evolved interferon-alpha polypeptides
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2010150242A3 (en) Immunogenic streptococcus pneumoniae peptides and peptide-multimers
MX2012001060A (es) Carbohidrato-oxidasas.
WO2009037253A3 (en) Polypeptides having tyrosinase activity and polynucleotides encoding same
WO2019210282A3 (en) Mycobacterial antigen compositions and methods of use
WO2015200354A3 (en) Enzymes that cleave non-glycosidic ether bonds between lignins or derivatives thereof and saccharides
MX2009011851A (es) Plasmidos de dna que tienen expresion y estabilidad mejoradas.
WO2011128892A3 (en) Modified forms of pneumococcal surface immunogenic protein b (psipb)
WO2016200787A3 (en) Compositions and treatments for haemophilus influenzae
UA103306C2 (en) Normal;heading 1;heading 2;heading 3;HUMAN C-FMS ANTIGEN BINDING PROTEINS
HK1230073A1 (en) Nutritive polypeptides and formulations thereof, and methods of production and use thereof
HK1227644A1 (en) Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof

Legal Events

Date Code Title Description
FG Grant or registration